CLOs on the Move

Immune Pharmaceuticals

www.immunepharma.com

 
Immune Pharmaceuticals is developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Blue Earth Diagnostics

Blue Earth Diagnostics (BED) is a privately held diagnostics company focused on the development and commercialisation of molecular imaging technologies.

STI Technologies

STI Technologies Limited (STI) is a health-care technology company that provides Canadian patients with greater choice and broader access to the best medications and health care products.

Clinical Research IO

Our first-of-its-kind software system lets clinical research investigators create e-source templates and use a mobile tablet to capture source data. Research sites can save time, improve accuracy and reduce protocol deviations through our autofill and data validation techniques. Our system also has patient scheduling, recruiting and financial management for a holistic, all-in-one enterprise solution.

Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Unicep Packaging

Unicep Packaging is a Sandpoint, ID-based company in the Healthcare, Pharmaceuticals, & Biotech sector.